Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNDX Syndax Pharmaceuticals

Closed 12-10 16:00:00 EST

20.62

+1.11

+5.69%

盘后20.70

+0.08+0.39%

19:57 EST

High20.80	Low19.11	Vol2.40M
Open19.65	D1 Closing19.51	Amplitude8.66%
Mkt Cap1.79B	Tradable Cap1.50B	Total Shares86.91M
T/O47.99M	T/O Rate3.30%	Tradable Shares72.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals","latestPrice":20.62,"timestamp":1765400400000,"preClose":19.51,"halted":0,"volume":2400751,"hourTrading":{"tag":"盘后","latestPrice":20.7,"preClose":20.62,"latestTime":"19:57 EST","volume":80090,"amount":1651508.591,"timestamp":1765414647489},"delay":0,"floatShares":72721425,"shares":86914838,"eps":-3.600392,"marketStatus":"Closed","change":1.11,"latestTime":"12-10 16:00:00 EST","open":19.65,"high":20.8,"low":19.11,"amount":47987363.34848,"amplitude":0.086622,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.600392,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765443600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":19.51,"preHourTrading":{"tag":"盘前","latestPrice":19.5442,"preClose":19.51,"latestTime":"09:11 EST","volume":168,"amount":3299.760912,"timestamp":1765375861027},"postHourTrading":{"tag":"盘后","latestPrice":20.7,"preClose":20.62,"latestTime":"19:57 EST","volume":80090,"amount":1651508.591,"timestamp":1765414647489},"volumeRatio":1.187935,"impliedVol":0.6671,"impliedVolPercentile":0.384},"requestUrl":"/m/hq/s/SNDX/tweets","defaultTab":"tweets","newsList":[{"id":"2590349574","title":"Syndax Pharmaceuticals Price Target Maintained With a $56.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349574","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349574?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:05","pubTimestamp":1765285500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 08:05 ET (13:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"1167606675","title":"Syndax Reports Strong Data for AML Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1167606675","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167606675?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:52","pubTimestamp":1765209128,"startTime":"0","endTime":"0","summary":"Shares of clinical-stage biopharmaceutical company Syndax Pharmaceuticals (SNDX) fell 3.2% in early Monday trading. The company presented updated data for its revumenib combination therapy at the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4109","ASH","LU2463526074.USD","SNDX"],"gpt_icon":0},{"id":"2589612337","title":"Syndax Reports Revumenib Achieves 92% Complete Remission Rate in Newly Diagnosed AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589612337","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589612337?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:50","pubTimestamp":1765194615,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL55MDVr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","SNDX","BK4585","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2588021781","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588021781","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588021781?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:01","pubTimestamp":1764795660,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on Decembe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199315/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","PSQ","QLD","SNDX","QID","USJW.SI","TQQQ","MNQmain","SQQQ",".IXIC","BK4139","TSYW.SI","USAW.SI","NQmain"],"gpt_icon":1},{"id":"2588065845","title":"Syndax Pharmaceuticals (SNDX): Evaluating Valuation After FDA Approval and NCCN Guideline Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2588065845","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588065845?lang=en_us&edition=fundamental","pubTime":"2025-12-03 03:23","pubTimestamp":1764703400,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (SNDX) is in the spotlight following a series of positive events, including expanded FDA approval for Revvvi Forge in relapse-refractory NPM1-mutated AML and inclusion in the NCCN guidelines. These developments could strengthen the company’s position with investors and in the broader treatment landscape.\nSee our latest analysis for Syndax Pharmaceuticals.\nAfter riding a wave of positive FDA and guideline news, Syndax’s share price has soared 39.56% in the past month and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-evaluating-valuation-after-fda-a-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-evaluating-valuation-after-fda-a-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2588724763","title":"Syndax Pharmaceuticals CEO to Join Evercore Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724763?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590457,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET. The event will feature Michael A. Metzger, Chief Executive Officer, and a live webcast will be available in the Investor section of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLbxY9Fq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00BGHQF748.EUR","BK4127","BK4588","BK4139","BK4112","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD","SNDX","EVR"],"gpt_icon":0},{"id":"2585849802","title":"Syndax Pharmaceuticals Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2585849802","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585849802?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:47","pubTimestamp":1763995620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 09:47 ET (14:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2585696284","title":"Syndax price target raised to $35 from $22 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2585696284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585696284?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:35","pubTimestamp":1763984126,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Syndax (SNDX) to $35 from $22 and keeps an Overweight rating on the shares. The firm updated the company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-35-from-22-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-35-from-22-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2585457330","title":"Barclays Remains a Buy on Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585457330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585457330?lang=en_us&edition=fundamental","pubTime":"2025-11-24 16:46","pubTimestamp":1763973961,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $35.00. Darout cov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-syndax-pharmaceuticals-sndx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-syndax-pharmaceuticals-sndx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2585157333","title":"Mizuho Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157333?lang=en_us&edition=fundamental","pubTime":"2025-11-21 04:15","pubTimestamp":1763669750,"startTime":"0","endTime":"0","summary":"In a report released today, from Mizuho Securities maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $45.00. In a report re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-syndax-pharmaceuticals-sndx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-syndax-pharmaceuticals-sndx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","SNDX"],"gpt_icon":0},{"id":"2584393656","title":"Why Syndax Pharmaceuticals (SNDX) Is Up 9.3% After Revuforj's FDA Nod and NCCN Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2584393656","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584393656?lang=en_us&edition=fundamental","pubTime":"2025-11-18 16:23","pubTimestamp":1763454229,"startTime":"0","endTime":"0","summary":"Earlier this month, Syndax Pharmaceuticals reported third quarter results showing a 21% increase in total revenue, fueled by strong uptake of its lead therapy Revuforj after it received FDA approval for expanded use and was included in the NCCN guidelines.\nAn interesting insight from this report is that these regulatory and clinical milestones, coupled with robust cash balances and a narrowed net loss, highlight Syndax's advancing operational progress and its strengthened foundation for...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-93-after-revuforjs-fda","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-93-after-revuforjs-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2583306679","title":"Syndax Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2583306679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583306679?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:07","pubTimestamp":1762967220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 12:07 ET (17:07 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2582537612","title":"Syndax price target lowered to $33 from $40 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2582537612","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582537612?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:36","pubTimestamp":1762950982,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Anupam Rama lowered the firm’s price target on Syndax (SNDX) to $33 from $40 and keeps an Overweight rating on the shares. The fir...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-price-target-lowered-to-33-from-40-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-price-target-lowered-to-33-from-40-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0820561818.USD","LU2552382132.HKD","LU1267930490.SGD","IE00BFXG1179.USD","LU0683600562.USD","LU2264538146.SGD","LU0234572021.USD","LU2106854487.HKD","LU0345770993.USD","LU2756315664.SGD","IE00BJTD4N35.SGD","LU0106261372.USD","LU0170899867.USD","LU1548497426.USD","BK4207","IE00BLSP4239.USD","LU1720051108.HKD","LU1629891620.HKD","LU0211326755.USD","LU1084165304.USD","LU2456880835.USD","LU0208291251.USD","BK4504","IE00BN8TJ469.HKD","IE000M9KFDE8.USD","IE00BKVL7J92.USD","LU0211326839.USD","LU0943347566.SGD","LU1244550577.SGD","LU2381873111.SGD","LU2746668461.USD","SNDX","LU0345770308.USD","LU0106831901.USD","IE00BHPRN162.USD","LU2552382058.USD","IE00BBT3K403.USD","BK4566","LU0820562030.AUD","LU0006306889.USD","LU0345769128.USD","LU0345769631.USD","LU0787776722.HKD","LU1670627923.USD","LU2430703095.HKD","LU1668664300.SGD","IE00B775SV38.USD","LU0942090050.USD","LU1551013342.USD","IE00BWXC8680.SGD"],"gpt_icon":0},{"id":"2581709932","title":"Syndax Pharmaceuticals Grants Stock Options to New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709932","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709932?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:01","pubTimestamp":1762376494,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. has granted inducement awards to four new employees, offering stock options to purchase up to 143,500 shares of common stock under its 2023 Inducement Plan. The options will vest over four years, with 25% of the shares vesting after one year and the remainder vesting in equal monthly installments over the following 36 months, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL93ks0F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","BK4585","IE00BKPKM429.USD","BK4112","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0},{"id":"2581545709","title":"Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581545709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581545709?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:01","pubTimestamp":1762376460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA5R74SY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2580756217","title":"UBS Adjusts Syndax Pharmaceuticals Price Target to $38 From $35, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2580756217","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580756217?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:41","pubTimestamp":1762270917,"startTime":"0","endTime":"0","summary":"Price: 14.81, Change: +1.05, Percent Change: +7.59","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNDX"],"gpt_icon":0},{"id":"1147724717","title":"Stock Track | Syndax Pharmaceuticals Soars 5.01% as Multiple Analysts Reiterate Buy Ratings and Raise Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1147724717","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147724717?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:40","pubTimestamp":1762270853,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (SNDX) saw its stock soar 5.01% in Tuesday's pre-market trading session, following a series of positive analyst reports and price target upgrades. The biotechnology company,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SNDX"],"gpt_icon":0},{"id":"1168376862","title":"Stock Track | Syndax Pharmaceuticals Soars 5.01% as Analysts Maintain Bullish Stance and Raise Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1168376862","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168376862?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:39","pubTimestamp":1762270792,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (SNDX) stock is soaring 5.01% in Tuesday's trading session, buoyed by a series of positive analyst reports and raised price targets. The biopharmaceutical company's shares are...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SNDX"],"gpt_icon":0},{"id":"2580755857","title":"Bank of America Securities Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580755857","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580755857?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:55","pubTimestamp":1762268154,"startTime":"0","endTime":"0","summary":"In a report released today, Jason Zemansky from Bank of America Securities reiterated a Buy rating on Syndax Pharmaceuticals, with a price target o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-its-buy-rating-for-syndax-pharmaceuticals-sndx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-its-buy-rating-for-syndax-pharmaceuticals-sndx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAC","SNDX"],"gpt_icon":0},{"id":"2580266730","title":"Syndax Pharmaceuticals Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2580266730","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580266730?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:14","pubTimestamp":1762265640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 09:14 ET (14:14 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0383},{"period":"1month","weight":0.2972},{"period":"3month","weight":0.2403},{"period":"6month","weight":0.8285},{"period":"1year","weight":0.2539},{"period":"ytd","weight":0.4758}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.1313},{"period":"1year","weight":0.1296},{"period":"ytd","weight":0.1654}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.047367},{"month":2,"riseRate":0.666667,"avgChangeRate":0.081651},{"month":3,"riseRate":0.555556,"avgChangeRate":0.051247},{"month":4,"riseRate":0.4,"avgChangeRate":0.014629},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019495},{"month":6,"riseRate":0.5,"avgChangeRate":-0.003538},{"month":7,"riseRate":0.6,"avgChangeRate":0.016261},{"month":8,"riseRate":0.6,"avgChangeRate":0.106119},{"month":9,"riseRate":0.5,"avgChangeRate":-0.031411},{"month":10,"riseRate":0.2,"avgChangeRate":-0.077781},{"month":11,"riseRate":0.6,"avgChangeRate":0.04592},{"month":12,"riseRate":0.4,"avgChangeRate":0.02837}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Syndax Pharmaceuticals,SNDX,Syndax Pharmaceuticals股票,Syndax Pharmaceuticals股票老虎,Syndax Pharmaceuticals股票老虎国际,Syndax Pharmaceuticals行情,Syndax Pharmaceuticals股票行情,Syndax Pharmaceuticals股价,Syndax Pharmaceuticals股市,Syndax Pharmaceuticals股票价格,Syndax Pharmaceuticals股票交易,Syndax Pharmaceuticals股票购买,Syndax Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}